3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Colorectal Neoplasms
21
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Neuroendocrine
2
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Ras-mutated Metastatic Colorectal Cancer
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma Metastatic
1
Neoplasms
1
Kidney Neoplasms
1
Histiocytosis
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastroesophageal Adenocarcinoma
1
Esophageal Squamous Cell Carcinoma
1
Interventions
Injections
13
pembrolizumab
10
tislelizumab
9
toripalimab
6
atezolizumab
4
Nivolumab
4
Carboplatin
3
trastuzumab deruxtecan
2
olaparib
2
lenvatinib
2
Pemetrexed
2
Paclitaxel
2
Oxaliplatin
2
Gemcitabine
2
Fluorouracil
2
Docetaxel
2
Cyclophosphamide
2
Cisplatin
2
Cetuximab
2
Bevacizumab
2
zimberelimab
1
talazoparib
1
spartalizumab
1
sotorasib
1
serabelisib
1
penpulimab
1
niraparib
1
nedaplatin
1
mirdametinib
1
fludarabine phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Solid Tumor
×
IFL protocol
×
1 year
×
Clear all
NCT05147350
2025-12-05
MINOTAUR
Debiopharm International SA
Phase 1
Terminated
38 enrolled
17 charts